Advanced in Bone Tumor

Ryuji Yasumatsu

Department Of Otolaryngology Head And Neck Surgery, 
Sayama, JP 
Advanced in Bone Tumor
Department Of Otolaryngology Head And Neck Surgery, 
Sayama, JP 
OverviewLocationsClinical Research

Overview

Ryuji Yasumatsu practices in Sayama, Japan. Mr. Yasumatsu is rated as an Advanced expert by MediFind in the treatment of Bone Tumor. His top areas of expertise are Sinus Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Gland Tumors, Glossectomy, and Laryngectomy.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 11 articles in the study of Bone Tumor.

Gender
Male

Locations

Department Of Otolaryngology Head And Neck Surgery, Sayama, Japan
Other Locations
Head And Neck Surgery, Japan
Department Of Otolaryngology Head And Neck Surgery, Osaka, Japan
Nishi, 8190935, Japan
Fukuoka, Japan
Higashi, 8128582, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab, Fluorouracil, Cisplatin, Carboplatin
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

107 Total Publications

The Role of Salvage Chemotherapy on Survival Outcomes Following Immune Checkpoint Inhibitor Therapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
The Role of Salvage Chemotherapy on Survival Outcomes Following Immune Checkpoint Inhibitor Therapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Journal: In vivo (Athens, Greece)
Published: June 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yasumatsu's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile